AACR 2026: Revolution's next prospect, Merck's reveal and a lung cancer battle [Yahoo! Finance]
Revolution Medicines, Inc. (RVMD)
Company Research
Source: Yahoo! Finance
The annual meeting of the American Association for Cancer Research is a chance for drug companies to showcase new and emerging ways to attack tumors. The gathering typically focuses on early research and clinical work, the studies developers use to build confidence in the larger and longer trials to come. This year's meeting was no different. Over the weekend, trial investigators revealed new data for the kind of immunotherapies and targeted medicines that have captured the attention of investors and drugmakers in recent years. Read on for a look at three of the more notable datasets at this year's meeting: Revolution's second act Over the last year or so, Revolution Medicines joined the ranks of the biopharmaceutical industry's most valuable companies. The recent success of its lead drug in testing against a tough-to-treat pancreatic tumor has positioned the company to unlock what's believed to be a more than $10 billion market opportunity. AACR is “buzzing with excitement
Show less
Read more
Impact Snapshot
Event Time:
RVMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVMD alerts
High impacting Revolution Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
RVMD
News
- Revolution Medicines (RVMD) had its "buy" rating reaffirmed by Stifel Nicolaus. They now have a $215.00 price target on the stock, up from $170.00.MarketBeat
- After a year of turmoil, cancer researchers see promising signs for mRNA vaccines [CNN]CNN
- After a year of turmoil, cancer researchers see promising signs for mRNA vaccines [CNN]CNN
- Revolution Medicines (RVMD) Jumps 54% on Stellar Drug Trial Results [Yahoo! Finance]Yahoo! Finance
- Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting [Yahoo! Finance]Yahoo! Finance
RVMD
Earnings
- 2/25/26 - Miss
RVMD
Sec Filings
- 4/17/26 - Form 4
- 4/17/26 - Form 8-K
- 4/16/26 - Form 8-K
- RVMD's page on the SEC website